Publications by authors named "P Browett"
Asciminib is a myristoyl site BCR::ABL1 inhibitor approved for patients with chronic-phase chronic myeloid leukemia (CP-CML) failing ≥2 prior lines of therapy. The Australasian Leukaemia and Lymphoma Group conducted the Asciminib Evaluation in Newly Diagnosed CML study to assess efficacy of asciminib for newly diagnosed CP-CML. Patients commenced asciminib 40 mg twice daily.
View Article and Find Full Text PDFThe primary analysis of MAGNOLIA, an open-label, single-arm, multicenter, phase 2 study, demonstrated that the next-generation Bruton tyrosine kinase (BTK) inhibitor zanubrutinib provided a high overall response rate (ORR) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL), with a favorable safety/tolerability profile. Presented here, is the final analysis of MAGNOLIA, performed to characterize the durability of response and longer-term safety and tolerability. Zanubrutinib (160 mg twice daily) was evaluated in 68 patients with R/R MZL who had received at least 1 anti-CD20-directed regimen.
View Article and Find Full Text PDFArticle Synopsis
- Marginal zone lymphoma (MZL) is a rare type of cancer that affects B-cells, and zanubrutinib is a new drug being tested for patients whose cancer has come back or hasn't responded to treatment.
- In a study with 68 patients, the results showed that 68.2% responded well to the treatment, with 25.8% having no signs of cancer after treatment.
- Most side effects from the drug were mild, like diarrhea and bruising, and the treatment was generally safe, leading to a conclusion that zanubrutinib could be effective for treating MZL.
Article Synopsis
- Paroxysmal nocturnal hemoglobinuria (PNH) causes uncontrolled complement activation leading to hemolysis, but treatment with C5 inhibitors may not fully prevent blood transfusion needs.
- A phase 2 trial involving 12 eculizumab-treated patients tested danicopan, an oral drug targeting an alternative complement pathway, showing a significant increase in hemoglobin levels and a reduction in transfusions over 24 weeks.
- Danicopan was well-tolerated with manageable side effects and demonstrated improved fatigue scores, indicating its potential as an effective treatment option for PNH patients.